Special Issue
Topic: Advances in Microbiome-Based Therapy for Cancer
A Special Issue of Microbiome Research Reports
ISSN 2771-5965 (Online)
Submission deadline: 31 Oct 2024
Guest Editor(s)
Special Issue Introduction
The special issue "Advances in Microbiome-Based Therapy for Cancer" is aimed at fostering interdisciplinary research at the intersection of microbiome studies and cancer treatment. Its primary objectives are to consolidate the latest research findings on the impact of the microbiome on cancer therapy, including its influence on immunotherapy, chemotherapy, and radiation therapy. Furthermore, it intends to provide practical guidelines for clinicians, researchers, and decision-makers to effectively harness the microbiome in cancer treatment, thereby improving treatment outcomes and patients' quality of life. Additionally, this special issue will explore how individualized cancer therapies can be developed based on the unique characteristics of a patient's microbiome, enhancing treatment precision. By summarizing existing knowledge and proposing future research directions, it seeks to stimulate greater interest among researchers in unraveling the intricate relationship between the microbiome and cancer therapy, thus advancing this burgeoning field of research.
To advance this research field, we aim to discuss the following topics but not limited to:
(1) The Role of Microbiome in Tumor Development: Association between the gut microbiome and cancer; mechanisms by which the microbiome influences tumor initiation, growth, and metastasis; microbiome's impact on the tumor microenvironment.
(2) Microbiome and Immunotherapy: Modulation of immunotherapy by the microbiome; gut microbiota's influence on anti-cancer immune responses; synergistic effects of the microbiome with immune checkpoint inhibitors.
(3) Microbiome and Drug Therapy: Microbiome's impact on chemotherapy drug metabolism and toxicity; microbiome-mediated drug therapy strategies; relationship between gut microbiota and drug resistance.
(4) Personalized Approaches Utilizing the Microbiome: Microbiome-based cancer prediction and diagnosis; development of personalized microbiome-based treatment strategies; prospects of microbiome-based interventions in clinical cancer management.
(5) Clinical Trials and Translational Medicine: Advancements in clinical trials for microbiome-based cancer therapy; translational challenges from laboratory research to clinical applications; application of microbiome-based treatments in cancer patients.
etc.
To advance this research field, we aim to discuss the following topics but not limited to:
(1) The Role of Microbiome in Tumor Development: Association between the gut microbiome and cancer; mechanisms by which the microbiome influences tumor initiation, growth, and metastasis; microbiome's impact on the tumor microenvironment.
(2) Microbiome and Immunotherapy: Modulation of immunotherapy by the microbiome; gut microbiota's influence on anti-cancer immune responses; synergistic effects of the microbiome with immune checkpoint inhibitors.
(3) Microbiome and Drug Therapy: Microbiome's impact on chemotherapy drug metabolism and toxicity; microbiome-mediated drug therapy strategies; relationship between gut microbiota and drug resistance.
(4) Personalized Approaches Utilizing the Microbiome: Microbiome-based cancer prediction and diagnosis; development of personalized microbiome-based treatment strategies; prospects of microbiome-based interventions in clinical cancer management.
(5) Clinical Trials and Translational Medicine: Advancements in clinical trials for microbiome-based cancer therapy; translational challenges from laboratory research to clinical applications; application of microbiome-based treatments in cancer patients.
etc.
Submission Deadline
31 Oct 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/mrr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=mrr&SpecialIssueId=MRR231101
Submission Deadline: 31 Oct 2024
Contacts: Fiona Yin, Managing Editor, editorialoffice@mrrjournal.net
Louise Xu, Assistant Editor, Louise@microbiomeresearchreports.net
Published Articles
Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin
Open Access Original Article 30 Oct 2024
DOI: 10.20517/mrr.2024.49
Views: Downloads: